Pharmacovigilance Market (By Clinical Trial Phase: Preclinical Phase I, Phase II, Phase III, and Phase IV; By Service Provider: In-house and Contract Outsourcing; By End User: Hospitals, Pharmaceutical Companies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 – 2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Process Flow Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmacovigilance Market 

5.1. COVID-19 Landscape: Pharmacovigilance Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmacovigilance Market, By Clinical Trial Phase

8.1. Pharmacovigilance Market, by Clinical Trial Phase Type, 2021-2030

8.1.1. Preclinical Phase I

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Phase II

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Phase III

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Phase IV

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Pharmacovigilance Market, By Service Provider Type

9.1. Pharmacovigilance Market, by Service Provider Type, 2021-2030

9.1.1. In-house

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Contract Outsourcing

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Pharmacovigilance Market, By End User

10.1. Pharmacovigilance Market, by End User Type, 2021-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Pharmaceutical Companies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Pharmacovigilance Market, By Therapeutic Area

11.1. Pharmacovigilance Market, by Therapeutic Area Type, 2021-2030

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Neurology

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Cardiology

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Respiratory Systems

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Pharmacovigilance Market, By Type

12.1. Pharmacovigilance Market, by Type, 2021-2030

12.1.1. Spontaneous Reporting

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Intensified ADR Reporting

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Targeted Spontaneous Reporting

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Cohort Event Monitoring

12.1.4.1. Market Revenue and Forecast (2017-2030)

12.1.5. EHR Mining

12.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Pharmacovigilance Market, By Process Flow

13.1. Pharmacovigilance Market, by Service Provider Type, 2021-2030

13.1.1. Case Data Management

13.1.1.1. Market Revenue and Forecast (2017-2030)

13.1.2. Signal Detection

13.1.2.1. Market Revenue and Forecast (2017-2030)

13.1.3. Risk Management System

13.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 14. Global Pharmacovigilance  Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.1.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.1.3. Market Revenue and Forecast, by End User (2017-2030)

14.1.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.1.5. Market Revenue and Forecast, by Type (2017-2030)

14.1.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.1.7. U.S.

14.1.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.1.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.1.7.3. Market Revenue and Forecast, by End User (2017-2030)

14.1.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.1.8. Market Revenue and Forecast, by Type (2017-2030)

14.1.8.1. Market Revenue and Forecast, by Process Flow (2017-2030) 

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.1.9.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.1.9.3. Market Revenue and Forecast, by End User (2017-2030)

14.1.9.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.1.10. Market Revenue and Forecast, by Type (2017-2030)

14.1.11. Market Revenue and Forecast, by Process Flow (2017-2030)

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030) 

14.2.5. Market Revenue and Forecast, by Type (2017-2030)

14.2.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.2.7.

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.8.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.8.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.9. Market Revenue and Forecast, by Therapeutic Area (2017-2030) 

14.2.10. Market Revenue and Forecast, by Type (2017-2030)

14.2.10.1. Market Revenue and Forecast, by Process Flow (2017-2030) 

14.2.11. Germany

14.2.11.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.11.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.11.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.12. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.2.13. Market Revenue and Forecast, by Type (2017-2030)

14.2.14. Market Revenue and Forecast, by Process Flow (2017-2030)

14.2.14.1.

14.2.15. France

14.2.15.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.15.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.15.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.15.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.2.16. Market Revenue and Forecast, by Type (2017-2030)

14.2.16.1. Market Revenue and Forecast, by Process Flow (2017-2030)

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.2.17.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.2.17.3. Market Revenue and Forecast, by End User (2017-2030)

14.2.17.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.2.18. Market Revenue and Forecast, by Type (2017-2030)

14.2.18.1. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.5. Market Revenue and Forecast, by Type (2017-2030)

14.3.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3.7. India

14.3.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.7.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.8. Market Revenue and Forecast, by Type (2017-2030)

14.3.9. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3.10. China

14.3.10.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.10.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.10.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.10.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.11. Market Revenue and Forecast, by Type (2017-2030)

14.3.11.1. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3.12. Japan

14.3.12.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.12.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.12.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.12.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.12.5. Market Revenue and Forecast, by Type (2017-2030)

14.3.12.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.3.13.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.3.13.3. Market Revenue and Forecast, by End User (2017-2030)

14.3.13.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.3.13.5. Market Revenue and Forecast, by Type (2017-2030)

14.3.13.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.5. Market Revenue and Forecast, by Type (2017-2030)

14.4.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4.7. GCC

14.4.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.7.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.8. Market Revenue and Forecast, by Type (2017-2030)

14.4.9. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4.10. North Africa

14.4.10.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.10.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.10.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.10.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.11. Market Revenue and Forecast, by Type (2017-2030)

14.4.12. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4.13. South Africa

14.4.13.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.13.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.13.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.13.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.13.5. Market Revenue and Forecast, by Type (2017-2030)

14.4.13.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.4.14.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.4.14.3. Market Revenue and Forecast, by End User (2017-2030)

14.4.14.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.4.14.5. Market Revenue and Forecast, by Type (2017-2030)

14.4.14.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.5.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.5.3. Market Revenue and Forecast, by End User (2017-2030)

14.5.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.5.5. Market Revenue and Forecast, by Type (2017-2030)

14.5.6. Market Revenue and Forecast, by Process Flow (2017-2030)

14.5.7. Brazil

14.5.7.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.5.7.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.5.7.3. Market Revenue and Forecast, by End User (2017-2030)

14.5.7.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.5.8. Market Revenue and Forecast, by Type (2017-2030)

14.5.8.1. Market Revenue and Forecast, by Process Flow (2017-2030)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Clinical Trial Phase (2017-2030)

14.5.9.2. Market Revenue and Forecast, by Service Provider (2017-2030)

14.5.9.3. Market Revenue and Forecast, by End User (2017-2030)

14.5.9.4. Market Revenue and Forecast, by Therapeutic Area (2017-2030)

14.5.9.5. Market Revenue and Forecast, by Type (2017-2030)

14.5.9.6. Market Revenue and Forecast, by Process Flow (2017-2030)

Chapter 15. Company Profiles

15.1. ICON Plc

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Pharmaceutical Product Development LLC

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Parexel International Corporation

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. IQVIA

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. Quanticate

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Bioclinica

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Covance Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Accenture Plc

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. IBM Corporation

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Novartis

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

PROCEED TO BUY

   USD 4500.00
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample